LANGaware, a cutting-edge AI-driven healthcare technology company, has recently announced a strategic partnership with Bioiatriki Healthcare Group, one of the largest private healthcare providers in Southeast Europe. This collaboration aims to transform the early detection and management of neurodegenerative conditions, including Alzheimer's Disease and Mild Cognitive Impairment (MCI), in Greece and Cyprus.
Innovative Collaboration for Advanced Healthcare Solutions
Within this partnership, Bioiatriki is integrating LANGaware's state-of-the-art AI-driven platform into its extensive network of more than 75 diagnostic centers. Utilizing AI technology, this platform can analyze digital biomarkers from voice and speech, enabling the early identification of cognitive and behavioral health conditions with unparalleled accuracy. By providing this innovative technology, Bioiatriki is empowering patients to recognize dementia symptoms at their initial stages, ultimately improving patient outcomes and quality of life.
Empowering Patients through Technology
Dr. Vassiliki Rentoumi, Founder and CEO of LANGaware, expressed excitement about the collaboration, stating, "We are thrilled to partner with Bioiatriki Healthcare Group to expand the reach of our groundbreaking technology to more patients. This partnership reflects our commitment to redefining early diagnosis and delivering effective, accessible solutions for global cognitive health management."
Efficient and Accurate Results
LANGaware's platform delivers rapid and precise outcomes within minutes, requiring only a short voice recording of the participant describing an image or daily activity. With a sensitivity of 90% and a specificity of 85% in detecting Alzheimer's Disease and MCI, the system significantly reduces the potential for misdiagnosis and unnecessary treatments. The integration of LANGaware's technology into Bioiatriki's healthcare services is expected to not only enhance patient outcomes but also improve healthcare efficiency by facilitating timely interventions and personalized support.
Advancing Cognitive Health Management
This collaboration represents a significant advancement in expanding access to sophisticated diagnostic services and underscores a shared dedication to enhancing cognitive health management. LANGaware's utilization of AI technology revolutionizes cognitive and behavioral health screening by offering early, precise, and objective detection of conditions. By leveraging speech analysis and proprietary voice and speech biomarkers, LANGaware contributes to more effective treatments, reduced healthcare burdens, and overall well-being.
For more information about LANGaware, please visit www.langaware.com.
Bioiatriki Healthcare Group, established in 1981, is a prominent provider of private healthcare services in Greece and Cyprus, managing over 75 diagnostic centers, two cutting-edge hospitals, and various specialized centers, catering to more than 3 million patients annually. To learn more, visit www.bioiatriki.gr.
Media Contacts
Virginia Korma
SOURCE LANGaware